Table 3.
The W/T1 and W/T2 ratios for selected genes commonly found in the ten gene signatures used in this analysis, in rank order from lowest to highest. CAIX is not found in any of the gene signatures, but included for comparison.
| Gene | Number of Signatures with the Gene |
W/T1 (1 Biopsy) |
W/T2 (2 Biopsies) |
|---|---|---|---|
| BNIP3 | 4 | 0.17 | 0.09 |
| AK3 | 4 | 0.19 | 0.10 |
| LDHA | 4 | 0.22 | 0.12 |
| KCTD11 | 5 | 0.25 | 0.14 |
| SLC2A1 | 5 | 0.26 | 0.15 |
| ADM | 4 | 0.28 | 0.16 |
| MRPS17 | 4 | 0.28 | 0.17 |
| NDRG1 | 5 | 0.30 | 0.17 |
| Lrp2bp | 4 | 0.32 | 0.19 |
| TPI1 | 4 | 0.33 | 0.20 |
| CAIX | 0 | 0.38 | 0.24 |
| DDIT4 | 4 | 0.56 | 0.39 |
| PGAM1 | 5 | 0.59 | 0.41 |
| C20ORF20 | 4 | 0.62 | 0.45 |
| ALDOA | 5 | 0.65 | 0.48 |
| PGK1 | 4 | 0.66 | 0.50 |
| VEGF | 5 | 0.70 | 0.54 |
| P4HA1 | 6 | 0.73 | 0.57 |
W/T1 – Within-tumor variance divided by the Total sample variance. Lower W/T1 implies greater capacity of a single biopsy to discriminate among tumors in the face of heterogeneity.
W/T2 – Within-tumor variance divided by the Total sample variance when two biopsies are available. Lower W/T2 implies greater capacity of two biopsies to discriminate among tumors in the face of heterogeneity.